Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorRoswell Park Cancer Institute

About this trial

To explore consumer responses to the announcement and implementation of new modified risk claims for Copenhagen and General Snus (brands of smokeless tobacco (ST) products) using a series of complementary and innovative research activities and methods.

Eligibility criteria

Qualifiers

Residing in one of the 8 counties of Western New York (Erie, Niagara, Cattaraugus, Chautauqua, Allegheny, Livingston, Genesee, Orleans, Wyoming).

Smoke cigarettes every day, at least 5 cigarettes per day, for at least 1 year.

Open to trying a non-combusted oral tobacco product.

Have access to a device (ie: computer/tablet/smartphone) with internet capabilities to participate in an online survey study.

Disqualifiers

Plan to quit smoking in the next 30 days.

Use of smokeless tobacco at least weekly in the last 6 months.

Lifetime use (that is, ever used at any time prior to the study) of Copenhagen or General Snus.

Unwilling or unable to follow protocol requirements.

Trial design

Treatments tested in this trial

  • Modified Risk - None
  • Modified Risk Claim

Treatment groups

160 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Roswell Park Cancer Institute

Lead sponsor

National Cancer Institute (NCI)

Collaborator